Isolated femoral endarterectomy: Impact of SFA TASC classification on recurrence of symptoms and need for additional intervention  by Al-Khoury, Georges et al.
From the Eastern Vascular Society
Isolated femoral endarterectomy: Impact of SFA
TASC classification on recurrence of symptoms
and need for additional intervention
Georges Al-Khoury, MD, Luke Marone, MD, Rabih Chaer, MD, Robert Rhee, MD, Jae Cho, MD,
Steven Leers, MD, Michel Makaroun, MD, and Navyash Gupta, MD, Pittsburgh, Pa
Objectives: Atherosclerotic occlusive disease of the femoral artery is associated with symptoms ranging from claudication
to tissue loss. This study examined the clinical and hemodynamic outcomes of isolated femoral endarterectomy (FEA) as
well as the predictors of symptom recurrence and need for further intervention.
Methods: Patients who underwent an isolated FEA between January 2001 and June 2008 were reviewed. Concurrent
superficial femoral artery (SFA) disease was classified into Trans Atlantic Inter-Societal Consensus (TASC) II categories
based upon angiographic findings. Hemodynamic success (HS) was defined as a postoperative ankle-brachial index (ABI)
increase of >0.15. Clinical improvement was classified by Rutherford criteria. Multivariate analysis was used to identify
predictors of clinical failure and need for additional intervention (AI). Kaplan-Meier estimates were used to determine the
likelihood of both over time.
Results: Ninety-five patients (105 limbs) with a mean age of 68.3  10.2 years were reviewed. Indications were severe
claudication in 68 (64.8%) limbs and critical limb ischemia (CLI) in 37 (35.2%). Mean preprocedural ABI was 0.57 
0.25. The SFA-popliteal segment was classified as: normal in 34% of limbs, TASCA 23%, B 19%, C 9%, andD in 15%. One
fatal myocardial infarction accounted for a procedural mortality of 0.95%. Morbidity was 6.7% (four hematomas and
three wound infections) and mean hospital stay was 2.5  3.1 days. Patency was 100% with a mean follow-up of 11
months (1-72). Complete resolution of symptoms was noted in 73.4% with some clinical improvement noted in 91% of
limbs. HS was achieved in 85.1% with a mean ABI increase of 0.27  0.20, and this correlated with >2 runoff vessels
(odds ratio [OR] 0.20; 95% confidence interval [CI] 0.04-0.96; P  .045). Kaplan-Meier estimates revealed that 83.8%
of patients with marked initial clinical improvement remained symptom free at 2 years, whereas only 28.6% in the group
with mild and moderate initial response maintained their clinical status. Freedom from AI at 2 years was 61.8%.
Multivariate analysis revealed that TASC C and D lesions (OR 9.3 [2.43-35.63] P  .001) and diabetes (OR 3.64
[1.01-13.15] P .048) were predictive of recurrent symptomswhile extensive endarterectomy and>2 vessel tibial runoff
decreased the need for AI.
Conclusion: FEA can achieve excellent immediate clinical and hemodynamic outcome in patients with claudication and
CLI; however, patients with diabetes and femoropopliteal TASC C and D lesions are likely to experience recurrent
symptoms. Long-term symptomatic improvement is associated with the degree of immediate clinical success as well as the
status of the run-off vessels. Limited FEA and poor tibial runoff are associated with the need for AI. (J Vasc Surg 2009;
50:784-9.)Isolated occlusive disease of the common femoral ar-
tery (CFA) is uncommon and more often associated with
aortoiliac or femoropopliteal atherosclerosis. Secondary to
the critical location of the CFA, at the junction between the
pelvic and lower extremity vasculature, complete occlusion
or stenosis can result in disabling intermittent claudication
and even critical limb ischemia depending on development
of collateral flow. Surgical management can be confined to
the CFA or associated with more complex open or endo-
vascular interventions. Nevertheless, isolated endarterec-
tomy is an often employed option when the occlusive
disease is primarily in the femoral bifurcation and has been
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784shown to be safe, effective, and durable with CFA patency
of 70% to 94% over 5 years.1-4
The choice to proceed with an isolated femoral endar-
terectomy (FEA) in the presence of additional outflow
disease remains mostly influenced by personal and institu-
tional experience and bias, as few reports have evaluated the
influence of outflow disease and other clinical parameters
on the outcome of this procedure. Some reports indicate
that long-term limb salvage may not be related to the
degree of ischemic symptoms at presentation and question
the benefit of additional distal bypass in the setting of
known outflow disease.1-3 Despite the excellent initial clin-
ical results of FEA, symptoms can recur over time, resulting
in additional interventions (AI), but no clear predictors
have been defined.5
The goals of the present study are to review the clinical
outcome of isolated FEA, the status of the outflow vessels,
and identify predictors of symptom recurrence and the
need for AI in the treatment of femoral atherosclerotic
occlusive disease.
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All patients undergoing surgical endarterectomy of the
common femoral artery between January 2001 and June
2008 were retrospectively identified. Patients who under-
went femoral thromboendarterectomy for acute thrombo-
sis, as well as patients with concomitant endovascular and
open interventions of the iliac and femoropopliteal arteries,
were excluded from analysis. Patients with remote prior
iliac angioplasty or stenting were included in this review.
Thus, the cohort included only those patients with chronic
atherosclerotic disease of the common femoral artery un-
dergoing isolated FEA. FEA involved the CFA as well as the
deep femoral artery (DFA) and the superficial femoral
artery (SFA) origins if indicated. This review was approved
by the University of Pittsburgh Institutional Review Board.
Patient characteristics, comorbidities, indications for
the endarterectomy, and clinical and hemodynamic follow-
up parameters were recorded. Occlusive disease of the
femoropopliteal segment was classified into Trans Atlantic
Inter-Societal Consensus (TASC) II categories based upon
review of available angiograms.6 The infrapopliteal runoff
was classified into two categories based upon the number of
patent vessels with continuity to the ankle mortise (1
vessel and 2 vessels).
Details of the operative procedures varied slightly by
surgeon, but they all followed standard practices. Control
of the proximal common femoral or external iliac arteries,
as well as soft segments of the SFA and DFA, was obtained
routinely. The endarterectomy was performed through a
longitudinal arteriotomy and ensured adequate flow was
preserved in the DFA by extending the endarterectomy
onto its origin. Closure was either primarily if the artery was
judged to be of adequate size or with a patch of Dacron
graft, vein, or an endarterectomized segment from a chron-
ically occluded SFA.
Postoperative follow-up included visits at 1, 6, and 12
months, and yearly thereafter. The patency of the endarter-
ectomy and recurrent disease was assessed with arterial
duplex scan during all visits. Hemodynamic assessment
included ankle-brachial index (ABI)measurement as well as
pulse volume recordings. Hemodynamic success (HS) was
defined as an increase in the postoperative ABI of 0.15.
Clinical improvement was defined as complete resolution
of the preoperative symptoms, or improvement in the
Rutherford class.7 Clinical failure was defined as no change
in symptoms or worsening of the Rutherford class. Symp-
tom recurrence was defined as recurrent symptoms after
initial postoperative improvement. AI was defined as any
reintervention (open or endoluminal) at the site of CFA
endarterectomy, and the inflow or outflow vessels of the
same extremity.
Multivariate analysis was used to identify predictors of
clinical failure and need for AI. All variables were screened
for univariate association with the clinical outcome of in-
terest at P .30. The identified variables were then assessed
in a forward stepwise manner to develop a final model.
Logistic regression was used to determine clinical improve-ment and HS; Cox proportional hazards modeling was
used to determine variables associated with the need for AI.
Kaplan-Meier estimates were used to estimate the likeli-
hood of AI and symptom recurrence over time.
RESULTS
One hundred five isolated FEA were performed on 95
patients. Ten patients underwent bilateral procedures (3
simultaneous). Demographic and patient clinical variables,
as well as postprocedure medications, are listed in Table I.
Indications for FEA included disabling claudication
(Rutherford class 2, or 3) in 68 limbs (64.8%) and critical
limb ischemia (CLI) (Rutherford class 4, 5, or 6) in 37
limbs (35.2%). Sixteen patients presented with both rest
pain and tissue loss (Table II).
One hundred angiograms on 100 limbs were available
for review. The severity of occlusive disease at all levels is
detailed in Table II. The common femoral artery stenosis
was evaluated on two angiographic views. The origin of the
DFA appeared to be involved in 35% of the limbs. The
femoropopliteal outflow was free of occlusive disease in
34% of the limbs. The infrapopliteal vessels were classified
based on 98 angiograms which were available for review:
two or more patent runoff vessels were identified in 73
limbs (74.5%). Only 25% of the limbs were free from both
iliac and femoropopliteal disease and 21% had 2 runoff
vessels.
General anesthesia was used during 65.7% of the pro-
cedures, spinal anesthesia in 31.4% and local anesthetic in
only 2.9%. The endarterectomy was limited to the CFA in
36 limbs (34.3%), extended to the SFA in 7 (6.7%), and was
extensive involving the origin of the DFA in 62 (59.1%).
Primary closure was performed in 17 limbs (16.2%), with
patch angioplasty in 88 (83.8%) (Dacron graft in 57 limbs,
vein in 25, and SFA patch in 6 of the limbs). The DFA was
patent in all the limbs after the FEA.Mean hospital stay was
2.5 3.1 days, ranging from 1 to 25 days. A single patient
Table I. Demographic and patient clinical characteristics
Characteristic
Percent or mean  SD (range)
(n  95)
Age (years) 68.3  10.2 (40-85)
Male 52 (54.7%)
Smoking status
Current 32 (33.7%)
Ever (former and current) 85 (89.5%)
History of diabetes mellitus 36 (37.9%)
Hypertension 83 (87.4%)
Dyslipidemia 63 (66.3%)
ESRD 7 (7.4%)
Coronary artery disease 57 (60.0%)
Cerebrovascular disease 17 (17.7%)
Postoperative medications
Aspirin 78 (82.1%)
Clopidogrel 50 (52.6%)
Statin 59 (62.1%)
ESRD, End-stage renal disease.with bilateral foot gangrene who underwent FEA died on
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in-hospital mortality (0.95%). There were seven local
wound complications (6.7%): four hematomas (one re-
quired operative evacuation) and three wound infections
(one abscess that required incision and drainage). One
patient remained on the ventilator for 24 hours.
Technical success rate was 100% at initial follow-up,
and all operative sites remained patent by Duplex scan
during subsequent follow-up (mean 11 months). Postop-
erative clinical assessment of symptoms was not available for
six limbs. For the remaining 99 limbs, initial clinical im-
provement was identified in 91%, eight procedures (8.1%)
did not result in any change in the preoperative symptoms
of the patients, and 1 patient reported worsening symptoms
following the intervention (Table III).
The characteristics of the limbs with marked and mod-
erate clinical improvement compared with the limbs with
minimal improvement or no change in the clinical symp-
toms are detailed in Table IV.
Due to the referral pattern and the large catchment area
Table II. Indications for surgery and outflow
characteristics of limbs
Indications for surgery
§
n  105
Moderate claudication 4 (3.8%)
Severe claudication 64 (60.9%)
Critical limb ischemia 37 (35.2%)
Pain at rest 27 (25.7%)
Minor tissue loss 20 (19.0%)
Major tissue loss 9 (8.6%)
TASC classification (femoropopliteal)*o
A 23 (23.0%)
B 19 (19.0%)
C 9 (9.0%)
D 15 (15.0%)
Runoff vessels
‡
0 3 (3.1%)
1 22 (22.4%)
2 21 (21.4%)
3 52 (53.1%)
TASC, Trans Atlantic Inter-Societal Consensus.
*n  100 (missing data on 5 limbs).
o34 limbs have normal vessels.
‡n  98 (missing data on 7 limbs).
§A limb can be positive for more than one Rutherford classification.
Table III. Postoperative assessment at the first follow-up
visit
Characteristic Percent*
Marked improvement 73 (73.7%)
Moderate improvement 8 (8.1%)
Minimal improvement 9 (9.1%)
No change 8 (8.1%)
Mildly worse 1 (1.0%)
Moderately worse 0
Significantly worse 0
*n  99 (missing data on 6 limbs).covered by our institution, the hemodynamic results werelacking in a number of patients. Preoperative ABI measure-
ments were available on 64 limbs with a mean of 0.57 
0.25. Postoperative ABI measurements were available on
81 limbs. In those patients with both pre- and postproce-
dural ABI for comparison, themean increase of the ABI was
0.27  0.20 with HS in 85.1% (40/47).
Preoperative variables predictive of outcomes were an-
alyzed in several models. In a model assessing hemody-
namic failure, multivariate analysis identified tibial runoff
2 vessels as a significant predictor of HS success (OR
0.20, 95% CI 0.04-0.96; P  .045). Two variables were
associated with recurrent postprocedural symptoms: TASC
II C and D lesions of the femoropopliteal segment, (OR
9.3 [2.43-35.63] P  .001) and diabetes mellitus, (OR
3.64 [1.01-13.15] P  .048). The initial clinical response
was found to be highly predictive of late outcomes. Kaplan-
Meier estimates revealed that 83.8% of the limbs with initial
marked clinical improvement remained symptom free at 2
years, whereas 28.6% of the limbs with initial moderate and
minimal response to FEA remained without recurrent
symptoms at 2 years (Fig 1).
During follow-up, 20 interventions were performed on
16 limbs at a median interval of 3 months (1-24). Six
patients required distal bypass to various target vessels and
1 patient required a proximal iliofemoral bypass. Thirteen
ipsilateral endovascular procedures were performed: 6 iliac
and 7 femoropopliteal. The six iliac interventions were all
performed within 15 months of the initial FEA for recur-
rent symptoms. Six patients had amputations, 5 major and
1 minor. Four limbs exhibited extensive gangrene at pre-
sentation and the FEA was successfully used to facilitate a
planned amputation healing. Twenty patients had minor
tissue loss of which 12 healed without additional interven-
tions. Three patients were lost to follow-up and two ampu-
tations were performed in this subgroup.
The freedom from AI was 61.8% at 2 years by Kaplan-
Meier analysis (Fig 2). In the model predicting the need for
any reintervention (iliac or SFA angioplasty and stenting,
major amputations, and distal bypass), end-stage renal dis-
ease (ESRD) (hazard ratio [HR] 3.90; 95% CI 0.77-19.59;
P  .10) was weakly associated with the need for AI.
Patients with more than two vessel tibial runoff (HR 0.29;
95% CI 0.09-0.95; P  .04), on statin therapy (HR 0.38;
95% CI 0.13-1.14; P .08), and extensive endarterectomy
involving the CFA, SFA, and DFA (HR 0.10; 95% CI
0.01-0.88; P  .04) were less likely to require subsequent
interventions.
DISCUSSION
Endarterectomy remains the preferred management
strategy for occlusive disease involving the CFA, as endo-
vascular treatment is usually avoided in this highly mobile
area with critical branches. FEA is often performed during
the course of a primary bypass or in combination with an
endovascular intervention since the disease rarely presents
in isolation. In our highly selected group of patients who
underwent FEA, we reviewed 100 angiograms which
ic Inte
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and femoropopliteal disease and 21% had2 runoff vessels.
Our results as well as other reports1-5,8-10 indicate that
endarterectomy remains effective as a solitary procedure for
severe claudication or rest pain even in the presence of distal
occlusive disease. A concomitant outflow bypass is not
always required, especially in the absence of suitable con-
duit, to achieve acceptable clinical improvement and HS.
FEA can also significantly augment the clinical response
after a prior proximal endovascular intervention. Treatment
strategy clearly depends on the evaluation of risk factors,
presenting symptoms, and the degree of flow restriction at
different anatomic levels. Isolated FEA is quite safe, with a
low complication rate and can be offered to higher-risk
Table IV. Characteristics of patients with marked (3) an
patients with minimal (1) improvement or no change (0
Clinical response n Claudication Rest pain
M
ti
3 73 54 17
Marked improvement (74%) (23%) (1
2 8 4 3
Moderate improvement (50%) (37.5%) (3
3, 2 81 58 20
(71.6%) (24.6%) (1
1, 0, 1 18 7 6
Minimal improvement and
no change (39%) (33%) (2
DM, Diabetes mellitus; ESRD, end-stage renal disease; TASC, Trans Atlant
Fig 1. Freedom from symptom recurrence after initial
terectomy (FEA).individuals. Our low mortality rate of 0.95% is quite typicalof other reports, which range from 1-1.8%.3,4 Although
occasional reports of wound morbidity can be as high as
20-30%,3,5 we only noted 2 patients that required surgical
interventions. With significant inflow disease, the proximal
stenotic flow should be relieved first, typically by endovas-
cular means, followed by the FEA. If the proximal disease
requires a surgical bypass, the femoral disease can be ad-
dressed at the same time. However, with distal disease, or
mild to moderate proximal inflow restriction, an isolated
FEA may still be offered prior to any other interventions.
Retrospective series of femoral endarterectomies thus
inherently include a variety of clinical and anatomical situ-
ations that are difficult to standardize and limit compari-
sons and sweeping conclusions. Although 65% of our
oderate (2) clinical improvement compared to the
ymptoms postoperatively
ss
Major
tissue loss DM ESRD
TASC C D
lesions
Tibial runoff
2 vessels
3 24 3 9 29
(4%) (33%) (4%) (12%) (40%)
1 3 1 4 4
) (12.5%) (37.5%) (12.5%) (50%) (50%)
4 27 4 13 33
(5%) (33%) (5%) (16%) (41%)
5 11 3 10 7
(28%) (61%) (16.6%) (55.5%) (39%)
r-Societal Consensus.
al improvement in patients treated with femoral endar-d m
) in s
inor
ssue lo
11
5%)
3
7.5%
14
7%)
5
8%)clinicisolated FEAs were performed for severe intermittent clau-
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different than some reports where CLI is present in 69% to
89% of patients1,2 but comparable to others with claudi-
cants in 59-69%.4,5,9 In addition, with concerns regarding
the effectiveness of isolated FEA, most series are limited by
cohort size and failure to objectively assess concomitant
inflow and outflow lesions and their impact on long-term
success. While Kechagias et al5 recently reported on 111
FEA performed over a period of 23 years, we recommend
isolated FEA liberally and our series averages 19 procedures
per year. Patency rates of FEA have traditionally been quite
good, attesting to the durability of the procedure varying
from 70% to 94% at 5 years.1-4 Our relatively short-term
patency rate of 100% prevented any analysis of anatomic
predictors of local failure, as no occlusions were detected
during our follow-up. Other series, however, indicate that
long-term patency was not affected by the addition of a
distal bypass or the presence of SFA occlusion.3 Patch
repair or primary closure, as well as the extension of the
endarterectomy onto the SFA or the DFA, had no effect on
patency.3 No differences were noted either between iso-
lated and hybrid procedures or between patients with and
without untreated SFA disease (93% at 1 year).9 The inclu-
sion of iliac endarterectomy by Melliere et al11 (92% pa-
tency at 5 years) or endovascular iliac angioplasty by Nelson
et al12 (84% patency at 1 year) also yielded similar patency
rates. Different techniques and anatomic situations thus
seem to uniformly result in good patency rates with little
effect. We believe our focus on ensuring a good DFA
outflow in all cases was key to our good patency outcomes.
Patency alone is obviously not an adequate measure of
the effectiveness of an isolated FEA. Outcome measures
Fig 2. Freedom from additional interventions in the
(FEA).related to clinical and hemodynamic response or the needfor AI are thus necessary to place the value of FEA in
perspective. Hoch et al2 found that the FEA was more
effective at relieving claudication and rest pain when the
SFA was patent with only an 81% clinical improvement.
Twenty of the 22 patients with CLI reported by Springhorn
et al1 experienced relief of symptoms initially; symptoms
recurred, however, in 89% of those followed up more than
12 months, reflecting the severity of disease in this selected
group. We similarly noted an initial clinical response in 91%
of our patients despite uniform patency, with many patients
developing recurrent symptoms requiring AI. It was inter-
esting to note that the degree of initial clinical response was
highly predictive of whether the benefit would be durable,
allowing an early determination of the need for additional
revascularizations especially when the procedure was per-
formed for tissue loss. Diabetes mellitus (OR 3.64), exten-
sive femoropopliteal disease manifested by TASC C and D
lesions (OR 9.3), and patients already on clopidogrel (OR
4.91) had a lower clinical response rate and may deserve
consideration for a more extensive initial intervention.
Although isolated FEA is successful and durable, fur-
ther interventions may be required in the long term, either
secondary to poor clinical response or to progression of the
disease proximal or distal to the CFA. Clearly the more
liberal the stance of offering isolated FEA early on, the
more likely that later interventions may be needed. Free-
dom from late revascularization has been reported to range
from 60% to 78% at 5 years and 42% at 15 years.5,9 Our
freedom from any AI including amputations of 62% at 2
years is similar to other reports. ESRD (HR 3.90) had a
weak association in our patients with the need of AI and
may represent a patient cohort that requires a more com-
rall population treated with femoral endarterectomyoveprehensive strategy. Tibial runoff of more than two vessels
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predicted a low requirement for future AI. The latter
finding suggests that an aggressive local procedure may be
necessary to achieve durable long-term outcomes. Other
reports have identified preoperative serum creatinine, CLI,
and congestive heart failure to predict AI.5,9 The quality of
theDFAwas linked by Cardon et al3 to later failures and the
need for an early femoropopliteal reconstruction. Since we
almost never offer isolated FEA to patients with poor
profundas and occluded SFAs, our analysis cannot address
this point directly. However, the risks associated with the
addition of a distal bypass procedure have to be balanced
against the potential need for re-intervention. In patients
with multiple co-morbidities and a limited functional sta-
tus, a femoral endarterectomy may be adequate to treat
their severe limiting claudication or rest pain symptoms. In
addition, if a femorotibial bypass is the only potential
outflow procedure and the patient lacks autogenous venous
conduit, an isolated femoral endarterectomy may suffice.
Hemodynamic success clearly depends on the thresh-
old increase in ABI deemed satisfactory. In this study we
applied stringent criteria of 0.15 increases in the ABI and
identified HS with FEA in 85% of our patients. SFA occlu-
sion has been reported to reduce the degree of hemody-
namic improvement,2 but tibial status seems to have the
highest association with HS in our analysis.
FEA has been associated with excellent long-term limb
salvage rates of 94% at 10 years and 85% at 15 years, despite
the presence of concomitant distal outflow disease.5
Mukherjee et al4 reported 100% limb salvage rates on
12 patients with critical limb ischemia.4 In our review, there
were five major amputations in 37 limbs with CLI (13.5%),
mostly associated with severe outflow disease, 2 patients
with TASC D and one with TASC C femoropopliteal
disease. The small numbers of CLI patients in our review do
not permit strong conclusions. However, limb salvage did
not appear to be influenced by the presence of severe
outflow disease or diabetes mellitus in a report by Spring-
horn et al1 on 20 limbs with CLI that underwent three
major amputations.
Although this is a large report with an analysis of the
angiographic findings, it has several limitations. It is a
retrospective analysis and, hence, is vulnerable to the inher-
ent bias associated with a variety of clinical indications and
no standardization of procedures. The mean follow-up
period was just under 1 year, preventing us from adequate
long-term predictions. Nevertheless, it does place into per-
spective some of the predictors of clinical outcomes associ-
ated with isolated FEA.
CONCLUSION
FEA can achieve excellent immediate clinical and he-
modynamic outcomes in patients with claudication and
CLI; however, patients with diabetes and femoropoplitealTASC C and D lesions are likely to experience recurrent
symptoms. Long-term symptomatic improvement is asso-
ciated with the degree of immediate clinical success as well
as the status of the runoff vessels. Limited FEA and poor
tibial runoff are associated with the need for AI.
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